High-risk human papillomavirus genotype distribution and attribution to cervical lesions in a Shanxi Province screening population
- PMID: 40753301
- PMCID: PMC12317979
- DOI: 10.1038/s41598-025-14228-0
High-risk human papillomavirus genotype distribution and attribution to cervical lesions in a Shanxi Province screening population
Abstract
To characterize the hrHPV genotype distribution and attribution to cervical lesions in the cohort of women screened in Shanxi Province. Data from the records of cervical cancer screening programs for rural women in Shanxi Province were retrospectively collected. Women who underwent primary human papillomavirus (HPV) screening between January 2014 and December 2019 were included. The attribution proportion of specific hrHPV types for different grades of cervical lesions was calculated by using the type contribution weighting and the proportional attribution methods to estimate the potential impact of HPV vaccines on CIN II + lesions. CIN II + lesions were observed mainly with HPV16 (65.85%), HPV18 (10.20%), HPV58 (10.20%), HPV52 (7.98%), HPV31 (4.66%), HPV33 (4.43%), HPV51 (2.22%) and HPV56 (2.22%). A total of 97.42% of all CIN II + lesions were attributed to HPV16, HPV18, HPV52, HPV58, HPV31, HPV33 and HPV35. A total of 75.4% (95% CI, 71.4-79.3) of CIN II + lesions were attributable to HPV16/18, and 21.1% (95% CI, 17.4-25.1) were attributable to the 5 additional types (HPV31/33/45/52/58) covered by the 9-valent vaccine. The prevalence of hrHPV infection among women in Shanxi Province was high, and HPV16, HPV18, HPV58, HPV52, HPV31, HPV33 and HPV35 had the highest attributable proportion of CIN II + lesions. The type-specific HPV prevalence and attribution proportion of cervical precancerous lesions should be taken into consideration in both clinical management and the design of preventive strategies.
Keywords: Attribution proportion; Cervical cancer; Cervical intraepithelial neoplasia; HPV genotyping; Human papillomavirus.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Competing interests: The authors declare no competing interests.
Figures
Similar articles
-
HPV vaccine impact: genotype-specific changes in cervical pre-cancer share similarities with changes in cervical screening cytology.J Natl Cancer Inst. 2025 Jul 1;117(7):1377-1386. doi: 10.1093/jnci/djaf055. J Natl Cancer Inst. 2025. PMID: 40069924 Free PMC article.
-
Independent risk factors for high-risk human papillomavirus infection among rural women in Shanxi Province, China: a population-based, case-control study.Arch Gynecol Obstet. 2023 Aug;308(2):551-559. doi: 10.1007/s00404-023-06959-0. Epub 2023 Feb 23. Arch Gynecol Obstet. 2023. PMID: 36814027
-
High-risk human papillomavirus diversity among indigenous women of western Botswana with normal cervical cytology and dysplasia.BMC Infect Dis. 2024 Oct 15;24(1):1163. doi: 10.1186/s12879-024-10058-z. BMC Infect Dis. 2024. PMID: 39407130 Free PMC article.
-
Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.Cochrane Database Syst Rev. 2018 May 9;5(5):CD009069. doi: 10.1002/14651858.CD009069.pub3. Cochrane Database Syst Rev. 2018. PMID: 29740819 Free PMC article.
-
Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions.Cochrane Database Syst Rev. 2013 Mar 28;2013(3):CD008054. doi: 10.1002/14651858.CD008054.pub2. Cochrane Database Syst Rev. 2013. PMID: 23543559 Free PMC article.
References
-
- Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J. Clin.68 (6), 394–424 (2018). - PubMed
-
- Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin.71 (3), 209–249 (2021). - PubMed
-
- Xing, N. Z. W. J. & Zhang, Y. Z. Shanxi Provincial Cancer Registry Annual Report. 2022. (2021).
-
- Di, J., Rutherford, S. & Chu, C. Review of the cervical cancer burden and Population-Based cervical cancer screening in China. Asian Pac. J. Cancer Prev.16 (17), 7401–7407 (2015). - PubMed